- New Funds to Support Projects in HIV Cure Discovery -
FOSTER CITY, Calif.--(BUSINESS WIRE)--Oct. 16, 2017--
Gilead Sciences, Inc. (NASDAQ:GILD) today announced the second round of
recipients of its HIV cure grants program. This new commitment will
provide $7.5 million to support five additional HIV cure research
initiatives led by top academic institutions and focused on
translational research and efficacy studies in preclinical models.
“Finding a cure for HIV is a formidable challenge to the scientific
community. Together with our newest grant recipients, all of whom have a
record of excellence in their research, we can take collective steps to
help end this devastating epidemic,” said William Lee, Ph.D., Executive
Vice President, Research, Gilead Sciences. “We are proud to support
these leaders in HIV research and are confident in their ability to make
meaningful and measurable contributions in this area of unmet medical
The following organizations and corresponding projects will receive
grants from Gilead to help fund their activities (Institution/Principal
University of California, San Francisco, School of Medicine,
Microbiology and Immunology, Chan Zuckerberg Biohub – Alexander
Marson, M.D., Ph.D. – An Integrated CRISPR Platform to Discover
Regulators of HIV Latency in Primary Human T Cells
Institute of Human Genetics, French National Center for Scientific
Research (CNRS) and University of Montpellier – Monsef Benkirane,
Ph.D. – Paving the Way Towards Elimination of HIV Persistent CD4T Cell
University of Massachusetts Medical School – Abraham L. Brass, M.D.,
Ph.D. – A CRISPR/Cas9 Screen to Discover HIV-1 Latency Factors
Frederick National Laboratory for Cancer Research, AIDS and Cancer
Virus Program – Jeffrey D. Lifson, M.D. – TLR Ligand Augmented, Tissue
Homing AIDS Virus-Specific Adoptive Cell Therapy to Target Viral
Dana-Farber Cancer Institute – Joseph G. Sodroski, M.D. – Unlocking
HIV-1 Env to Deplete Viral Reservoirs
The HIV cure grants program, initially announced in February 2016,
underscores Gilead’s commitment to cure and ultimately eradicate HIV and
AIDS through its research and development and philanthropic leadership.
The first set of HIV cure grants, totaling more than $22 million, were
awarded to 12 projects in January 2017.
For nearly 30 years, Gilead has been a leading innovator in the field of
HIV, driving advances in treatment, prevention, testing and linkage to
care, and cure research. In further efforts to end the HIV epidemic,
Gilead is conducting early-stage clinical research to identify novel
agents and strategies that could play a role in eradicating HIV
infection in the body.
Gilead’s corporate giving program aims to reduce health disparities,
provide access, advance medical education and support local communities.
In 2016, Funders Concerned About AIDS (FCAA) recognized Gilead as the
leading corporate global funder of HIV/AIDS programs, and second overall
behind the Bill & Melinda Gates Foundation.
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops
and commercializes innovative therapeutics in areas of unmet medical
need. The company’s mission is to advance the care of patients suffering
from life-threatening diseases. Gilead has operations in more than 30
countries worldwide, with headquarters in Foster City, California.
For more information on Gilead Sciences, please visit the company’s
website at www.gilead.com,
follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs
at 1-800-GILEAD-5 or 1-650-574-3000
View source version on businesswire.com: http://www.businesswire.com/news/home/20171016005352/en/
Source: Gilead Sciences, Inc.
Gilead Sciences, Inc.
Sung Lee, 650-524-7792